Trevena, Inc. (NASDAQ:TRVN) – Oppenheimer Holdings issued their Q1 2018 earnings estimates for Trevena in a report issued on Monday. Oppenheimer Holdings analyst D. Archila anticipates that the biopharmaceutical company will post earnings per share of ($0.18) for the quarter. Oppenheimer Holdings currently has a “Buy” rating and a $5.00 price target on the stock. Oppenheimer Holdings also issued estimates for Trevena’s Q2 2018 earnings at ($0.17) EPS, Q3 2018 earnings at ($0.21) EPS and Q4 2018 earnings at ($0.26) EPS.

Trevena (NASDAQ:TRVN) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.06. During the same quarter last year, the firm earned ($0.57) EPS.

ILLEGAL ACTIVITY NOTICE: “Research Analysts Set Expectations for Trevena, Inc.’s Q1 2018 Earnings (TRVN)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.watchlistnews.com/research-analysts-set-expectations-for-trevena-inc-s-q1-2018-earnings-trvn/1702243.html.

TRVN has been the subject of several other reports. Zacks Investment Research cut shares of Trevena from a “buy” rating to a “hold” rating in a research report on Friday, August 25th. Needham & Company LLC decreased their price target on shares of Trevena from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, November 8th. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Trevena in a research report on Wednesday, November 8th. Barclays PLC cut shares of Trevena from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $15.00 to $2.50 in a research report on Monday, October 16th. Finally, Cowen and Company restated a “buy” rating and issued a $10.00 price target on shares of Trevena in a research report on Friday, August 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. Trevena presently has a consensus rating of “Buy” and an average price target of $8.75.

Trevena (NASDAQ:TRVN) opened at $1.57 on Tuesday. Trevena has a 12-month low of $1.35 and a 12-month high of $8.00. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.92 and a quick ratio of 4.92.

Several institutional investors and hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System increased its position in shares of Trevena by 0.5% during the second quarter. California State Teachers Retirement System now owns 97,107 shares of the biopharmaceutical company’s stock worth $223,000 after buying an additional 500 shares during the period. American International Group Inc. increased its position in shares of Trevena by 7.1% during the first quarter. American International Group Inc. now owns 27,541 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 1,816 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Trevena by 12.1% during the first quarter. Goldman Sachs Group Inc. now owns 59,522 shares of the biopharmaceutical company’s stock worth $218,000 after buying an additional 6,402 shares during the period. Rhumbline Advisers increased its position in shares of Trevena by 30.1% during the second quarter. Rhumbline Advisers now owns 64,251 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 14,880 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of Trevena by 4.2% during the first quarter. Geode Capital Management LLC now owns 390,429 shares of the biopharmaceutical company’s stock worth $1,432,000 after buying an additional 15,839 shares during the period. Institutional investors own 57.71% of the company’s stock.

About Trevena

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Earnings History and Estimates for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.